Cargando…
Effect of Liraglutide on Vascular Inflammation Evaluated by [(64)Cu]DOTATATE
Quantification of vascular inflammation before and after treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may help reveal mechanistic pathways underlying the cardiovascular benefits of these drugs. We assessed change in vascular inflammation in the carotid arteries over 26 weeks...
Autores principales: | Zobel, Emilie H., Ripa, Rasmus S., von Scholten, Bernt J., Curovic, Viktor Rotbain, Diaz, Lars Jorge, Hansen, Tine W., Rossing, Peter, Kjaer, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391433/ https://www.ncbi.nlm.nih.gov/pubmed/34441365 http://dx.doi.org/10.3390/diagnostics11081431 |
Ejemplares similares
-
Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [(64)Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial
por: Jensen, Jacob K., et al.
Publicado: (2021) -
Effect of liraglutide on expression of inflammatory genes in type 2 diabetes
por: Zobel, Emilie H., et al.
Publicado: (2021) -
Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial
por: Zobel, Emilie H, et al.
Publicado: (2021) -
Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial
por: Wretlind, Asger, et al.
Publicado: (2022) -
Effect of Liraglutide on Arterial Inflammation Assessed as [(18)F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Ripa, Rasmus S., et al.
Publicado: (2021)